We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Arthur J. Gallagher (AJG) in Q2 Earnings?
Read MoreHide Full Article
Arthur J. Gallagher & Co. (AJG - Free Report) is slated to report second-quarter 2019 results on Jul 25, after market close. The company delivered positive earnings surprise in three of the last four quarters.
Let’s see how things are shaping up for this announcement.
Arthur J. Gallagher’s second-quarter results are likely to benefit from solid performance of Brokerage and Risk Management segments.
Its compelling product portfolio along with strong domestic and international operations is likely to aid fees and commissions. The Zacks Consensus Estimate for fees is pegged at $450 million, indicating an upside of 6.6% on a year-over-year basis. The consensus mark for commissions stands at $786 million, implying 14.2% growth.
Organic sales as well as strategic mergers and acquisitions are expected to drive revenues. The Zacks Consensus Estimate for revenues is pegged at $1.95 billion, indicating an increase of 9% from the year-ago reported figure.
An improved interest rate environment is likely to boost net investment income.
Expenses are likely to increase due to higher compensation and operating expenses.
The Zacks Consensus Estimate for second-quarter earnings is pegged at 62 cents, same as the year-ago reported figure.
What Our Quantitative Model Says
Our proven model does not conclusively show that Arthur J. Gallagher is likely to beat estimates this reporting cycle. This is because the stock does not have the right combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold).
Earnings ESP: Arthur J. Gallagher has an Earnings ESP of +2.43%. This is because the Most Accurate Estimate of 62 cents is higher than the Zacks Consensus Estimate of 61 cents. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: Arthur J. Gallagher has a Zacks Rank #4 (Sell).
We caution against Zacks Rank #4 or 5 (Strong Sell) stocks going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some stocks from the insurance industry with the perfect mix of elements to surpass estimates this time around.
Lincoln National Corporation (LNC - Free Report) has an Earnings ESP of +0.52% and a Zacks Rank of 3. The company is set to release second-quarter earnings on Jul 31.
The Hartford Financial Services Group, Inc. (HIG - Free Report) has an Earnings ESP of +0.63% and a Zacks Rank #3. The company is slated to announce second-quarter earnings on Aug 1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in Store for Arthur J. Gallagher (AJG) in Q2 Earnings?
Arthur J. Gallagher & Co. (AJG - Free Report) is slated to report second-quarter 2019 results on Jul 25, after market close. The company delivered positive earnings surprise in three of the last four quarters.
Let’s see how things are shaping up for this announcement.
Arthur J. Gallagher’s second-quarter results are likely to benefit from solid performance of Brokerage and Risk Management segments.
Its compelling product portfolio along with strong domestic and international operations is likely to aid fees and commissions. The Zacks Consensus Estimate for fees is pegged at $450 million, indicating an upside of 6.6% on a year-over-year basis. The consensus mark for commissions stands at $786 million, implying 14.2% growth.
Organic sales as well as strategic mergers and acquisitions are expected to drive revenues. The Zacks Consensus Estimate for revenues is pegged at $1.95 billion, indicating an increase of 9% from the year-ago reported figure.
An improved interest rate environment is likely to boost net investment income.
Expenses are likely to increase due to higher compensation and operating expenses.
The Zacks Consensus Estimate for second-quarter earnings is pegged at 62 cents, same as the year-ago reported figure.
What Our Quantitative Model Says
Our proven model does not conclusively show that Arthur J. Gallagher is likely to beat estimates this reporting cycle. This is because the stock does not have the right combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold).
Earnings ESP: Arthur J. Gallagher has an Earnings ESP of +2.43%. This is because the Most Accurate Estimate of 62 cents is higher than the Zacks Consensus Estimate of 61 cents. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Arthur J. Gallagher & Co. Price and EPS Surprise
Arthur J. Gallagher & Co. price-eps-surprise | Arthur J. Gallagher & Co. Quote
Zacks Rank: Arthur J. Gallagher has a Zacks Rank #4 (Sell).
We caution against Zacks Rank #4 or 5 (Strong Sell) stocks going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some stocks from the insurance industry with the perfect mix of elements to surpass estimates this time around.
Marsh & McLennan Companies, Inc. (MMC - Free Report) is set to report second-quarter earnings on Jul 30 and has an Earnings ESP of +0.63%. The company has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lincoln National Corporation (LNC - Free Report) has an Earnings ESP of +0.52% and a Zacks Rank of 3. The company is set to release second-quarter earnings on Jul 31.
The Hartford Financial Services Group, Inc. (HIG - Free Report) has an Earnings ESP of +0.63% and a Zacks Rank #3. The company is slated to announce second-quarter earnings on Aug 1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>